IPM's ring study results published

December 1, 2016, International Partnership for Microbicides (IPM)
The monthly dapivirine ring, developed by the International Partnership for Microbicides. Credit: Andrew Loxley

The International Partnership for Microbicides (IPM) announced today that The New England Journal of Medicine (NEJM) has published results from The Ring Study, a Phase III clinical trial of IPM's vaginal ring to prevent HIV. The study's key findings, announced earlier this year, show that a vaginal ring that slowly releases the antiretroviral drug (ARV) dapivirine over the course of one month safely helps reduce the risk of HIV infection in women.

Published on World AIDS Day, today's article is an important addition to the available data on the efficacy of the dapivirine to protect against HIV/AIDS, the leading cause of death for of reproductive age worldwide. UNAIDS recently warned that current prevention strategies are not decreasing the rate of new HIV infections quickly enough to end the epidemic—and women are especially at risk. The dapivirine ring, developed by IPM, is the first long-acting, self-initiated HIV prevention method shown to work in two large-scale studies—IPM's Ring Study and its sister study, ASPIRE, led by the US National Institutes of Health-funded Microbicide Trials Network (MTN).

The Ring Study data published in NEJM show the dapivirine ring safely reduced HIV infection by 31 percent overall among all women in the trial. This is similar to primary results seen in ASPIRE, published previously in NEJM. The ASPIRE data also showed that HIV risk was cut by more than half in women over 21 and recent exploratory analyses presented in July show that among women who used the ring consistently, the risk of HIV infection was reduced by at least 56 percent. Subgroup analyses suggest the ring cut HIV risk by 75 percent or more with near-perfect use.

"The publication of the Ring Study data reinforces the growing evidence base about the ring's safety and efficacy, and its potential role in HIV prevention," said Dr. Zeda Rosenberg, founder and chief executive officer of IPM. "Women continue to become infected at alarming rates, especially in Africa, and need new options they can use to help protect their health."

Next Steps for the Ring:

  • Open-label extension studies (OLEs): Two open-label studies—DREAM and HOPE—are underway in Africa to provide the ring to former Phase III participants; gain insight into when, why and how women use the ring; and collect extended safety data. The OLEs will help us understand real-world use of the ring now that women know the product is safe and helps prevent HIV.
  • Regulatory submissions: IPM will seek regulatory approval for the ring. This process includes compiling a comprehensive dossier of data on the ring for regulatory agency review. IPM plans to submit the first application for licensure in Q2 2017.
  • Next-generation products: IPM is developing a three-month dapivirine-only ring as well as a three-month dapivirine-contraceptive ring designed to help prevent both HIV and unintended pregnancy. Next-generation products will build on current progress by increasing efficacy and addressing overlapping health needs.

Explore further: Dapivirine ring did not confer drug resistance among women who acquired HIV in ASPIRE

Related Stories

Dapivirine ring did not confer drug resistance among women who acquired HIV in ASPIRE

October 18, 2016
Among women who acquired HIV during ASPIRE, researchers found no differences in the frequency and patterns of HIV drug resistance between those assigned to use the ring containing an anti-retroviral (ARV) drug called dapivirine ...

Women facing intimate partner violence were less likely to use vaginal ring

October 18, 2016
Of the 2,629 women enrolled in the ASPIRE study, a large HIV prevention trial of a monthly vaginal ring, only 85 participants (fewer than 5 percent) reported that they were subject to or feared intimate partner violence. ...

HOPE open-label study of vaginal ring for preventing HIV begins

July 18, 2016
Women who took part in ASPIRE, a trial that found a vaginal ring containing an antiretroviral (ARV) drug called dapivirine was safe and helped protect against HIV, will soon be offered the opportunity to use the ring as part ...

Women report vaginal ring for preventing HIV had little effect on sexual intercourse

October 18, 2016
Most women who used an experimental vaginal ring for HIV prevention report that the physical act of sex was largely unaffected by using the product, which is inserted monthly for continuous wear. This finding is among several ...

Researchers complete ASPIRE Phase III trial of vaginal ring for HIV prevention in women

June 29, 2015
In a first for HIV prevention, an international team of researchers have completed follow-up of participants enrolled in a pivotal Phase III trial that tested the safety and effectiveness of a vaginal ring for preventing ...

Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase III trial

February 22, 2016
A vaginal ring containing an antiretroviral (ARV) drug called dapivirine that women use for a month at a time was safe and helped protect against HIV in a large-scale clinical trial involving more than 2,600 women in Africa, ...

Recommended for you

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

Researchers find clues to AIDS resistance in sooty mangabey genome

January 3, 2018
Peaceful co-existence, rather than war: that's how sooty mangabeys, a monkey species found in West Africa, handle infection by SIV, a relative of HIV, and avoid developing AIDS-like disease.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.